The impact of workload changes and staff availability on IV chemotherapy services

Abstract

Objectives. To determine the extent of change in intravenous (IV) chemotherapy workload in recent years, the availability of specialist pharmacy and nursing staff to carry out this work and the service implications of any mismatch between these two parameters. To determine the volume of chemotherapy currently administered for metastatic colorectal cancer (MCRC) to allow assessment of the possible workload implication of a switch to oral fluoropyrimidine therapy. Design. An anonymous postal survey of pharmacist members of the British Oncology Pharmacy Association (BOPA) and their nursing colleagues. Response. 0f 104 questionnaires distributed, 54 were returned (response rate 51.9%). Data summary. Ninety-three per cent of pharmacists reported an increase averaging 178% (range 15]/500%) in the volume of IV chemotherapy being prepared by their units over the last five years, with the average unit currently producing 896 (range 110]/5000) doses each month. Pharmacist and nurse recruitment difficulties were also reported almost universally. The combination of these two factors led to reported problems for both staff and patients, with a majority of nursing and pharmacy staff noting increased staff stress and prolonged patient waiting times. A significant minority of departments have already taken, generally undesirable, steps to address a significant imbalance between chemotherapy workload and service capacity, including restricting clinical trial activity and other aseptic dispensing work. Conclusions. Rapid expansion in the use of IV cytototoxic chemotherapy has resulted in pharmacy and nursing services facing severe pressure. Imaginative solutions are necessary if safe and efficient services are to be maintained. These may include increased use of oral fluorpyrimidines for the first-line treatment of MCRC, which this survey indicates accounts for about 10% of IV chemotherapy administered in the UK.

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer

“…Although the Mayo regimen was used as a comparator in international trials at that time, this was not universally accepted in the UK. Survey results suggested that the Mayo, de Gramont and MdG (Cheeseman et al, 2002) regimens were all widely used in the UK (Summerhayes, 2003). This is broadly supported by the results of an earlier survey (Seymour et al, 1997).…”

Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study

“…Over the next 10-20 years the trend could be a move towards more oral administration given at home (Allwood et al, 2002;Powell et al, 1991). The demand for chemotherapy treatment in developed countries continues to increase at around 10% increase per year (Department of Health) (DoH, 2004;Health Canada, 2004;Summerhayes, 2003). The trend is also towards higher and more efficacious doses due to medical sciences increasing ability to control the side-effects of these drugs (Catimel and Droz, 1995;Mughal, 1994;Mundy et al, 2003;Stiakaki et al, 1999).…”

Simultaneous determination of a selected group of cytostatic drugs in water using high‐performance liquid chromatography–triple‐quadrupole mass spectrometry

“…In developed countries, demand for chemotherapy treatment continues to increase at around 10% per year [15,16]. Nowadays, there are over 50 cytotoxic drugs used routinely in chemotherapy in hospitals ( [15], www.fda.gov/cder/cancer/druglistframe.htm).…”